{"id":641749,"date":"2023-03-08T18:14:01","date_gmt":"2023-03-08T18:14:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=641749"},"modified":"2023-03-08T18:14:01","modified_gmt":"2023-03-08T18:14:01","slug":"gastroparesis-market-to-witness-growth-by-20222032-analyzed-by-delveinsight-key-companies-relamorelin-tradipitant-velusetrag-ng101","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/gastroparesis-market-to-witness-growth-by-20222032-analyzed-by-delveinsight-key-companies-relamorelin-tradipitant-velusetrag-ng101_641749.html","title":{"rendered":"Gastroparesis Market to Witness Growth by (2022-2032), Analyzed by DelveInsight | Key Companies &#8211; Relamorelin, Tradipitant, Velusetrag, NG101"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1678303041.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Gastroparesis Market to Witness Growth by (2022-2032), Analyzed by DelveInsight | Key Companies - Relamorelin, Tradipitant, Velusetrag, NG101\" src=\"https:\/\/www.abnewswire.com\/uploads\/1678303041.jpeg\" alt=\"Gastroparesis Market to Witness Growth by (2022-2032), Analyzed by DelveInsight | Key Companies - Relamorelin, Tradipitant, Velusetrag, NG101\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The Gastroparesis market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gastroparesis pipeline products will significantly revolutionize the Gastroparesis market dynamics.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong>&ldquo;Gastroparesis Market Insights, Epidemiology, and Market Forecast-2032&Prime;<\/strong> report offers an in-depth understanding of the Gastroparesis, historical and forecasted epidemiology as well as the Gastroparesis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The Gastroparesis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current &amp; forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers &amp; barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To Know in detail about the Gastroparesis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/gastroparesis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Gastroparesis Market Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Gastroparesis Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Gastroparesis, which is a translated meaning of &ldquo;stomach paralysis&rdquo;, is a digestive disorder characterized by delayed gastric emptying of solid food in the absence of mechanical obstruction of the stomach, resulting in the cardinal symptoms of early satiety, postprandial fullness, nausea, vomiting, belching, and bloating.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Gastroparesis Market Report:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Gastroparesis market size was valued at <strong>USD 3,219.82 Million<\/strong> in 2020 and is anticipated to grow with a significant CAGR during the study period (2019-2032)&nbsp;<\/li>\n<li>The Total prevalent population of gastroparesis in the 7MM was <strong>34,243,119<\/strong> in 2020. These cases of gastroparesis in the 7MM&nbsp;<\/li>\n<li>As per estimates, the highest prevalence of gastroparesis was observed in the United States with <strong>13,306,122 cases<\/strong> in 2020&nbsp;<\/li>\n<li><strong>Key Gastroparesis Companies:<\/strong> Allergan, Vanda Pharmaceuticals, Theravance Biopharma, Neurogastrx, and others<\/li>\n<li><strong>Key Gastroparesis Therapies:<\/strong> Relamorelin, Tradipitant, Velusetrag, NG101, and others&nbsp;<\/li>\n<li>The Gastroparesis epidemiology based on gender analyzed that a higher percentage of prevalence of Gastroparesis was observed for females, in comparison to males, in all the 7MM countries&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free sample for the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/gastroparesis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Gastroparesis Market Report<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Gastroparesis market report covers a descriptive overview and comprehensive insight of the Gastroparesis Epidemiology and Gastroparesis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) &amp; Japan.)<\/li>\n<li>The Gastroparesis market report provides insights on the current and emerging therapies.<\/li>\n<li>Gastroparesis market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/li>\n<li>The Gastroparesis market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Gastroparesis market.<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Gastroparesis epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/gastroparesis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Gastroparesis Epidemiological Insights<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Gastroparesis Market<\/strong> &nbsp;<\/p>\n<p style=\"text-align: justify;\">The dynamics of the Gastroparesis market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. &nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Gastroparesis Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Gastroparesis Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Gastroparesis market report proffers epidemiological analysis for the study period 2019&ndash;2032 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Prevalence of Gastroparesis<\/li>\n<li>Prevalent Cases of Gastroparesis by severity<\/li>\n<li>Gender-specific Prevalence of Gastroparesis<\/li>\n<li>Diagnosed Cases of Episodic and Chronic Gastroparesis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Gastroparesis Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gastroparesis market or expected to get launched during the study period. The analysis covers Gastroparesis market uptake by drugs, patient uptake by therapies, and sales of each drug.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\">The report also covers the Gastroparesis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major Gastroparesis market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/gastroparesis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Gastroparesis market forecast<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Gastroparesis Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Relamorelin:<\/strong> Allergan<\/li>\n<li><strong>Tradipitant:<\/strong> Vanda Pharmaceuticals<\/li>\n<li><strong>Velusetrag:<\/strong> Theravance Biopharma<\/li>\n<li><strong>NG101:<\/strong> Neurogastrx<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Gastroparesis Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Dynamic Gastroparesis Pipeline<\/li>\n<li>Emerging Biomarkers and Targets<\/li>\n<li>Rising Prevalence of Diabetes<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Gastroparesis Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Study Period: 2019&ndash;2032<\/strong><\/li>\n<li><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/li>\n<li><strong>Key Gastroparesis Companies:<\/strong> Allergan, Vanda Pharmaceuticals, Theravance Biopharma, Neurogastrx, and others<\/li>\n<li><strong>Key Gastroparesis Therapies:<\/strong> Relamorelin, Tradipitant, Velusetrag, NG101, and others<\/li>\n<li><strong>Gastroparesis Therapeutic Assessment:<\/strong> Gastroparesis current marketed and Gastroparesis emerging therapies<\/li>\n<li><strong>Gastroparesis Market Dynamics:&nbsp;<\/strong>Gastroparesis market drivers and Gastroparesis market barriers&nbsp;<\/li>\n<li><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/li>\n<li><strong>Gastroparesis Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Gastroparesis Market Access and Reimbursement&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Gastroparesis Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Lack of Clinical Evidence by Prescription Drugs<\/li>\n<li>Economic Burden<\/li>\n<li>Failure of Therapies<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Gastroparesis Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for Gastroparesis<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of Gastroparesis<\/p>\n<p style=\"text-align: justify;\">4. Gastroparesis Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Gastroparesis Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Gastroparesis Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Gastroparesis Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Gastroparesis&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Gastroparesis Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Gastroparesis Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Gastroparesis Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Gastroparesis Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Gastroparesis Market Analysis (2019&ndash;2032)<\/p>\n<p style=\"text-align: justify;\">14. Gastroparesis Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Gastroparesis Market Drivers<\/p>\n<p style=\"text-align: justify;\">16. Gastroparesis Market Barriers<\/p>\n<p style=\"text-align: justify;\">17.&nbsp; Gastroparesis Appendix<\/p>\n<p style=\"text-align: justify;\">18. Gastroparesis Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Gastroparesis treatment, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/gastroparesis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Gastroparesis Medications<\/a> <\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=gastroparesis-market-to-witness-growth-by-20222032-analyzed-by-delveinsight-key-companies-relamorelin-tradipitant-velusetrag-ng101\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/r-and-d-analysis\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/r-and-d-analysis<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/r-and-d-analysis\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=gastroparesis-market-to-witness-growth-by-20222032-analyzed-by-delveinsight-key-companies-relamorelin-tradipitant-velusetrag-ng101\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Gastroparesis market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gastroparesis pipeline products will significantly revolutionize the Gastroparesis market dynamics. DelveInsight&rsquo;s &ldquo;Gastroparesis Market Insights, Epidemiology, and Market &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/gastroparesis-market-to-witness-growth-by-20222032-analyzed-by-delveinsight-key-companies-relamorelin-tradipitant-velusetrag-ng101_641749.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-641749","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/641749","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=641749"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/641749\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=641749"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=641749"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=641749"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}